Käynnissä olevat tutkimukset Suomessa
Akuutti lymfaattinen leukemia
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR’S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL
CARCINOMA
|
Inotuzumab
PF-05208773 |
B1931022 |
Alzheimerin tauti
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers |
AAB-001 |
B2521001
3133K1-3000 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers |
AAB-001 |
B2521002
3133K1-3001 |
| A Phase 3, Multicenter, Parallel-Group , Long Term Safety and Tolerability Trial of Bapineuzumab (AAB 001, ELN115727) in Subjects With Alzheimer's Disease Who Pariticipated In Study 3133K1-3000. |
AAB-001 |
B2521003
3133K1-3002 |
| A Phase 3 Extension, Multicenter, Long Term Safety and Tolerability Trial of Bapineuzumab (AAB 001, ELN115727) in Subjects With Alzheimer's Disease Who are Apolipoprotein E 4 Carriers and Pariticipated In Study 3133K1-3001-US. |
AAB-001 |
B2521004
3133K1-3003 |
Diabeteksesta johtuva makulaödeema
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| AN OPEN LABEL, ONE YEAR, NON-COMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREOUS PEGAPTANIB SODIUM IN PATIENTS WITH DIABETIC MACULAR EDEMA |
Pegaptanib |
A5751036 |
Ei-pienisoluinen keuhkosyöpä
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT LEAST ONE PRIOR CHEMOTHERAPY |
Dacomitinib
PF-00299804 |
A7471009 |
| PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS |
Crizotinib |
A8081014 |
GIST
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A NON-INTERVENTIONAL RETROSPECTIVE CORRELATION OF TUMOR MUTATION STATUS TO CLINICAL BENEFIT FORM THE SU011248, A6181036 TREATMENT PROTOCOL TITLED: A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE RERRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE |
Sunitinib Malate |
A6181199 |
Hemofilia A
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A Non-Randomized, Open-label Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Refacto AF in Previously Treated Subjects than Twelve Years of Age with Severe Hemophilia A (FVIII:C <1%) |
RefactoAF |
B1831005
3082B2-4433 |
HIV- infektio
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS WITH CCR5-TROPIC HIV-1 |
Maraviroc |
A4001095 |
Krooninen alaselkäkipu
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS POPULATION |
Pregabalin |
A0081256 |
Krooninen myeloottinen leukemia
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome Positive Leukemias |
SKI-606 |
B1871006
3160A4-200 |
Lasten epilepsia
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL
ONSET SEIZURE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP,
MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS
ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL
ONSET SEIZURE
|
Pregabalin |
A0081041 |
Levinnyt munuaissyöpä
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN
PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL
CARCINOMA
|
PF-04856884 (CVX-060) |
B1131004 |
| A Randomized Trial of Temsirolimus versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy |
CCI-779 |
B1771003
3066K1-404 |
Meningokokki B:n ehkäisy
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND RLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS AGED ≥11 TO <19 YEARS |
MnB rLP2086 and Repevax |
B1971010 |
A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY,
TOLERABILITY, AND IMMUNOGENICITY OF RLP2086 VACCINE WHEN ADMINISTERED IN EITHER 2- OR 3-DOSE REGIMENS IN HEALTHY SUBJECTS AGED ≥11 TO <19 YEARS |
MnB rLP2086-vaccine |
B1971012 |
Nivelreuma
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF TASOCITINIB (CP 690,550) FOR TREATMENT OF RHEUMATOID ARTHRITIS |
Tofacitinib,
CP-690,550 |
A3921024 |
| A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP 690,550 |
CP-690,550 |
A3921029 |
Psoriasis
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A PHASE 3, MULTI-SITE,OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS |
Tofacitinib |
A3921061 |
| A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS |
Tofacitinib |
A3921111 |
Selkärankareuma
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL
SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSION |
Etanercept |
B1801031 |
Tupakasta vieroitus
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO- CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS |
Varenicline Tartrate |
A3051123 |
Yleistynyt ahdistuneisuushäiriö
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER |
Pregabalin |
A0081147 |
Yliaktiivinen rakko
| TUTKIMUKSEN NIMI |
MOLEKYYLI |
PROTOKOLLA |
| A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL TO CONFIRM THE EFFICACY OF 8MG FESOTERODINE COMPARED TO 4MG FESOTERODINE |
Fesoterodine |
A0221095 |
|
|